- Home
- RARE vs VRRM Comparison
RARE vs VRRM Comparison
Compare RARE & VRRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- VRRM
- Stock Information
- Founded
- RARE 2010
- VRRM 1987
- Country
- RARE United States
- VRRM United States
- Employees
- RARE N/A
- VRRM N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- VRRM Transportation Services
- Sector
- RARE Health Care
- VRRM Consumer Discretionary
- Exchange
- RARE Nasdaq
- VRRM Nasdaq
- Market Cap
- RARE 3.3B
- VRRM 3.8B
- IPO Year
- RARE 2014
- VRRM N/A
- Fundamental
- Price
- RARE $37.17
- VRRM $24.37
- Analyst Decision
- RARE Strong Buy
- VRRM Strong Buy
- Analyst Count
- RARE 17
- VRRM 4
- Target Price
- RARE $92.29
- VRRM $27.38
- AVG Volume (30 Days)
- RARE 974.0K
- VRRM 930.7K
- Earning Date
- RARE 07-31-2025
- VRRM 05-07-2025
- Dividend Yield
- RARE N/A
- VRRM N/A
- EPS Growth
- RARE N/A
- VRRM N/A
- EPS
- RARE N/A
- VRRM 0.21
- Revenue
- RARE $590,689,000.00
- VRRM $892,731,000.00
- Revenue This Year
- RARE $18.94
- VRRM $7.87
- Revenue Next Year
- RARE $28.93
- VRRM $7.44
- P/E Ratio
- RARE N/A
- VRRM $114.97
- Revenue Growth
- RARE 33.46
- VRRM 6.90
- 52 Week Low
- RARE $29.59
- VRRM $19.51
- 52 Week High
- RARE $60.37
- VRRM $31.03
- Technical
- Relative Strength Index (RSI)
- RARE 55.64
- VRRM 60.20
- Support Level
- RARE $35.73
- VRRM $23.46
- Resistance Level
- RARE $36.22
- VRRM $24.31
- Average True Range (ATR)
- RARE 1.37
- VRRM 0.48
- MACD
- RARE 0.25
- VRRM -0.00
- Stochastic Oscillator
- RARE 90.54
- VRRM 63.58
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About VRRM Verra Mobility Corporation
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three segments namely Commercial Services, Government Solutions, and Parking Solutions. It generates maximum revenue from the Commercial Services segment. The commercial Services segment delivers tolling and violation management services to rental car companies, commercial fleet vehicle owners, and violation issuing authorities.